Citron Marc L
Albert Einstein College of Medicine, Bronx, New York, USA.
Breast Care (Basel). 2008;3(4):251-255. doi: 10.1159/000148914. Epub 2008 Aug 20.
The dose intensity of adjuvant chemotherapy for breast cancer is an important predictor of clinical outcome. Dose-dense chemotherapy increases the dose intensity of the regimen by delivering standard-dose chemotherapy with shorter intervals between the treatment cycles. The rationale for dose-dense therapy stems from the Norton-Simon hypothesis: Sequential, consecutive dosing of chemotherapy using single or a combination of agents increases the dose density over alternating dosing, improving results. Supporting adjuvant studies, such as C9741, and the ensuing clinical experience indicate an improved disease-free and overall survival. Dosedense adjuvant chemotherapy improves clinical outcomes without increasing toxicity.
乳腺癌辅助化疗的剂量强度是临床预后的重要预测指标。剂量密集化疗通过在更短的治疗周期间隔内给予标准剂量化疗来提高方案的剂量强度。剂量密集治疗的理论依据源于诺顿-西蒙假说：使用单一药物或联合药物进行序贯、连续给药化疗比交替给药增加了剂量密度，从而改善治疗效果。支持性的辅助研究，如C9741研究以及后续的临床经验表明，无病生存期和总生存期均有所改善。剂量密集辅助化疗可改善临床预后且不增加毒性。
